Paying for Cures publications

Moradian, R., Meshesha, T., Trusheim, M., & Barlow, J. F. (2024). Payer and Developer perspectives on alternative payment models. Expert Review of Pharmacoeconomics & Outcomes Research, 24(2), 293–301. 

Quinn, C., Ciarametaro, M., Sils, B., Phares, S., & Trusheim, M. (2023). Medicaid best price reforms to enable innovative payment models for cell and gene therapies. Expert Review of Pharmacoeconomics & Outcomes Research, 23(2), 191–203.

Young, C. M., Trusheim, M., & Quinn, C. (2022). Data for modelling US projections of product approvals, patients treated, and product revenues for durable cell and gene therapies. Data in Brief, 41, 107891.

Eichler, H.-G., Trusheim, M., Schwarzer-Daum, B., Larholt, K., Zeitlinger, M., Brunninger, M., Sherman, M., Strutton, D. and Hirsch, G. (2022), Precision Reimbursement for Precision Medicine: Using Real-World Evidence to Evolve From Trial-and-Project to Track-and-Pay to Learn-and-Predict. Clin. Pharmacol. Ther., 111: 52-62.

C. Young; C. Quinn; M. Trusheim. Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. Drug Discovery Today (2021). DOI: 10.1016/j.drudis.2021.09.001

Ivica NA, Young CM. Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020). Healthcare. 2021; 9(8):1062.

J.F. Barlow; M.W. Courtney; M. Trusheim. Payer Perspectives on Gene Therapy Reimbursement. Pharmaceutical Executive, 04/2020

J.F. Barlow; M.W. Courtney; M. Trusheim. Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies. Pharmaceutical Executive, 01/09/2020

J.F. Barlow; M. Yang; R. Teagarden. Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies? Value in Health, 06/2019, 10.1016/j.jval.2018.12.004

J. Barlow; R. Teagarden; M. Trusheim. Precision Financing of Durable, Potentially Curative Therapies. Pharmaceutical Executive, 01/2019

M.R. Trusheim; W.M. Cassidy; P.B. Bach. Alternative State-Level Financing for Hepatitis C Treatment—The "Netflix Model" JAMA, 10/29/2018, 10.1001

D. Han; D.S. Mytelka; G.L. Warren; M. Ciarametaro; M. Trusheim. Improving Management of Gene and Cell Therapies: The Orphan Reinsurer and Benefit Manager (ORBM)., 2018

M.R. Trusheim; A.A. Shrier; Z. Antonijevic; R.A. Beckman; R.K. Campbell; C. Chen; K.T. Flaherty; J. Loewy; D. Lacombe; S. Madhavan; H.P. Selker; L.J. Esserman. PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms. Clinical Pharmacology & Therapeutics, 2016, 10.1002/cpt.514

R. Teagarden; T.F. Unger; G. Hirsch. Access and availability of orphan drugs in the United States: advances or cruel hoaxes? Expert Opinion on Orphan Drugs, 2014, 10.1517/21678707.2014.947265